Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors

被引:40
作者
Teixeira, C. [1 ]
Serradji, N. [1 ]
Maurel, F. [1 ]
Barbault, F. [1 ]
机构
[1] Univ Paris Diderot, Lab ITODYS, F-75013 Paris, France
关键词
gp120; inhibitors; 3D-QSAR; CoMFA; CoMSIA; Docking; MOLECULAR SIMILARITY INDEXES; ENVELOPE GLYCOPROTEIN; VIRAL ENVELOPE; ARGININE CONJUGATE; ANALYSIS COMSIA; CD4; RECEPTOR; BINDING; BMS-378806; DYNAMICS; FUSION;
D O I
10.1016/j.ejmech.2009.03.028
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. Recently, 36 analogs compounds of BMS-806 were synthesized and their biological activity evaluated. Based on these compounds, a molecular docking was firstly performed with BMS-806 to the gp120 cavity in order to get a representative ligand conformation for the 3D-QSAR process. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were then conducted for these 36 compounds. CoMFA and CoMSIA models give reliable correlative and predictive abilities but the CoMFA model performance was slightly better than CoMSIA. CoMFA contours were analysed and have been correlated to the gp120 viral protein. The discussion indicates several key fragment positions on the ligands and their implications on the gp120 protein binding. The computational approach used in this paper provides reliable clues for further design of small molecules gp120/CD4 inhibitors based on the BMS-806. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:3524 / 3532
页数:9
相关论文
共 37 条
[31]   Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor [J].
Vermeire, K ;
Schols, D .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (10) :1199-1212
[32]  
VONG R, 1988, Journal of Chemometrics, V2, P281, DOI 10.1002/cem.1180020406
[33]  
WALD S, 1984, CHEMOMETRICS MATH ST
[34]   A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding [J].
Wang, HGH ;
Williams, RE ;
Lin, PF .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (15) :1785-1793
[35]   Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]lpyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806):: A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions [J].
Wang, T ;
Zhang, ZX ;
Wallace, OB ;
Deshpande, M ;
Fang, HQ ;
Yang, Z ;
Zadjura, LM ;
Tweedie, DL ;
Huang, S ;
Zhao, F ;
Ranadive, S ;
Robinson, BS ;
Gong, YF ;
Riccardi, K ;
Spicer, TP ;
Deminie, C ;
Rose, R ;
Wang, HGH ;
Blair, WS ;
Shi, PY ;
Lin, PF ;
Colonno, RJ ;
Meanwell, NA .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (20) :4236-4239
[36]   The antigenic structure of the HIV gp120 envelope glycoprotein [J].
Wyatt, R ;
Kwong, PD ;
Desjardins, E ;
Sweet, RW ;
Robinson, J ;
Hendrickson, WA ;
Sodroski, JG .
NATURE, 1998, 393 (6686) :705-711
[37]   Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein [J].
Xiang, SH ;
Kwong, PD ;
Gupta, R ;
Rizzuto, CD ;
Casper, DJ ;
Wyatt, R ;
Wang, LP ;
Hendrickson, WA ;
Doyle, ML ;
Sodroski, J .
JOURNAL OF VIROLOGY, 2002, 76 (19) :9888-9899